Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 13.5 mg - drug delivery system, transdermal - excipient ingredients: ascorbyl palmitate; povidone; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 9 mg - drug delivery system, transdermal - excipient ingredients: ascorbyl palmitate; povidone; dl-alpha-tocopherol; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - rotigotine, quantity: 4.5 mg - drug delivery system, transdermal - excipient ingredients: dl-alpha-tocopherol; ascorbyl palmitate; povidone; sodium metabisulfite; methylated trimethylated silica; heptane - parkinson's disease: neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease. restless legs syndrome: neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 80 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium metabisulfite; phenol; water for injections; sulfuric acid; disodium edetate - for the treatment of serious infections of the following type where they are caused by susceptible organisms: skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis.,aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics.,tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. if susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should be instituted.,note that bacterial cultures should bo obtained before and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. if the organisms are resistant, other appropriate therapy should be instituted. in patients in whom gram-negative septicaemia, neonatal sepsis or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cefalosporin and an aminoglycoside may be indicated, tobramycin therapy may be initiated before results of susceptibility studies are obtained. the decision to continue tobramycin therapy should be based upon the results of susceptibility studies, the severity of infection and the important additional concepts discussed in the product information leaflet.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - antithrombin iii, quantity: 1000 iu - drug delivery system - excipient ingredients: - thromboltrol-vf is indicated in patients with hereditary deficiency of atiii under the following circumstances. a) prophylactic administration for the prevention of thrombosis and pulmonary embolism in surgery, pregnancy and childbirth (see precautions: use in pregnancy). b) therapeutic administration in thrombosis or pulmonary embolism.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - aciclovir -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 500 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - antineoplastic chemotherapy - treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic and meningeal leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemia. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methotrexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. high dose therapy - the use of very high doses is made possible by vials for injection containing 500 mg and 1000 mg (see precautions). diseases treated with these doses administered in the form of single-drug or combination therapy, include osteogenic sarcoma, acute leukaemia, bronchogenic carcinoma and epidermoid carcinoma of the head and n

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - glyceryl trinitrate, quantity: 50 mg - drug delivery system, transdermal - excipient ingredients: lactose monohydrate; dimeticone; colloidal anhydrous silica; polyethylene terephthalate; aluminium; ethylene/vinyl acetate copolymer; polyvinyl chloride; trichlorotrifluoroethane; simethicone - indicated for the prevention of chronic stable angina pectoris due to coronary artery disease.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bupivacaine hydrochloride monohydrate, quantity: 105.4 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - bupivacaine injection is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery - field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in post operative pain or labour pain. - field block (minor nerve block amd infiltration). the choice of 2 strengths, 0.25% and 0.5%, makes it possible to vary the degree of motor blockade.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - daunorubicin, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - indications as at 22 november 2004 : daunorubicin injection is indicated for the treatment of the following: acute lymphocytic (lymphoblastic) leukaemia: daunorubicin is usually reserved for use in cases shown to be resistant to other drugs. however, combined treatment with daunorubicin, vincristine and a steroid has been used in the early stages of this disease. acute myeloblastic leukaemia: daunorubicin has been used in all stages, alone or in combination with other cytotoxic agents (e.g. cytarabine). disseminated solid tumours: daunorubicin has been investigated for use in these tumours and found to be effective in some cases of disseminated neuroblastoma and rhabdomyosarcoma.